Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16


T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells.

Pont MJ, Oostvogels R, van Bergen CAM, van der Meijden ED, Honders MW, Bliss S, Jongsma MLM, Lokhorst HM, Falkenburg JHF, Mutis T, Griffioen M, Spaapen RM.

Cancer Immunol Res. 2019 May;7(5):797-804. doi: 10.1158/2326-6066.CIR-18-0137. Epub 2019 Mar 19.


Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.

Oostvogels R, Jak M, Raymakers R, Mous R, Minnema MC.

Br J Haematol. 2018 Oct;183(1):60-67. doi: 10.1111/bjh.15504. Epub 2018 Aug 6.


In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review.

Oostvogels R, Uniken Venema SM, de Witte M, Raymakers R, Kuball J, Kröger N, Minnema MC.

Bone Marrow Transplant. 2017 Sep;52(9):1233-1240. doi: 10.1038/bmt.2017.141. Epub 2017 Jul 10. Review.


A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma.

Franssen LE, Roeven MWH, Hobo W, Doorn R, Oostvogels R, Falkenburg JHF, van de Donk NW, Kester MGD, Fredrix H, Westinga K, Slaper-Cortenbach I, Spierings E, Kersten MJ, Dolstra H, Mutis T, Schaap N, Lokhorst HM.

Bone Marrow Transplant. 2017 Oct;52(10):1378-1383. doi: 10.1038/bmt.2017.118. Epub 2017 Jun 5.


Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients.

Oostvogels R, Kneppers E, Minnema MC, Doorn RC, Franssen LE, Aarts T, Emmelot ME, Spierings E, Slaper-Cortenbach I, Westinga K, Goulmy E, Lokhorst HM, Mutis T.

Bone Marrow Transplant. 2017 Feb;52(2):228-237. doi: 10.1038/bmt.2016.250. Epub 2016 Nov 14.


Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.

Nijhof IS, Franssen LE, Levin MD, Bos GMJ, Broijl A, Klein SK, Koene HR, Bloem AC, Beeker A, Faber LM, van der Spek E, Ypma PF, Raymakers R, van Spronsen DJ, Westerweel PE, Oostvogels R, van Velzen J, van Kessel B, Mutis T, Sonneveld P, Zweegman S, Lokhorst HM, van de Donk NWCJ.

Blood. 2016 Nov 10;128(19):2297-2306. doi: 10.1182/blood-2016-07-729236. Epub 2016 Sep 19.


RhoB Mediates Phosphoantigen Recognition by Vγ9Vδ2 T Cell Receptor.

Sebestyen Z, Scheper W, Vyborova A, Gu S, Rychnavska Z, Schiffler M, Cleven A, Chéneau C, van Noorden M, Peigné CM, Olive D, Lebbink RJ, Oostvogels R, Mutis T, Schuurhuis GJ, Adams EJ, Scotet E, Kuball J.

Cell Rep. 2016 May 31;15(9):1973-85. doi: 10.1016/j.celrep.2016.04.081. Epub 2016 May 19.


Minor histocompatibility Ags: identification strategies, clinical results and translational perspectives.

Oostvogels R, Lokhorst HM, Mutis T.

Bone Marrow Transplant. 2016 Feb;51(2):163-71. doi: 10.1038/bmt.2015.256. Epub 2015 Oct 26. Review.


Altered peptide ligands revisited: vaccine design through chemically modified HLA-A2-restricted T cell epitopes.

Hoppes R, Oostvogels R, Luimstra JJ, Wals K, Toebes M, Bies L, Ekkebus R, Rijal P, Celie PH, Huang JH, Emmelot ME, Spaapen RM, Lokhorst H, Schumacher TN, Mutis T, Rodenko B, Ovaa H.

J Immunol. 2014 Nov 15;193(10):4803-13. doi: 10.4049/jimmunol.1400800. Epub 2014 Oct 13.


Identification of minor histocompatibility antigens based on the 1000 Genomes Project.

Oostvogels R, Lokhorst HM, Minnema MC, van Elk M, van den Oudenalder K, Spierings E, Mutis T, Spaapen RM.

Haematologica. 2014 Dec;99(12):1854-9. doi: 10.3324/haematol.2014.109801. Epub 2014 Aug 22.


The importance of the osmolality gap in ethylene glycol intoxication.

Oostvogels R, Kemperman H, Hubeek I, ter Braak EW.

BMJ. 2013 Nov 27;347:f6904. doi: 10.1136/bmj.f6904. No abstract available.


Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1.

Oostvogels R, Minnema MC, van Elk M, Spaapen RM, te Raa GD, Giovannone B, Buijs A, van Baarle D, Kater AP, Griffioen M, Spierings E, Lokhorst HM, Mutis T.

Leukemia. 2013 Mar;27(3):642-9. doi: 10.1038/leu.2012.277. Epub 2012 Oct 1.


Systemic vasculitis in myelodysplastic syndromes.

Oostvogels R, Petersen EJ, Chauffaille ML, Abrahams AC.

Neth J Med. 2012 Mar;70(2):63-8. Review.


The diagnostic value of history and physical examination for COPD in suspected or known cases: a systematic review.

Broekhuizen BD, Sachs AP, Oostvogels R, Hoes AW, Verheij TJ, Moons KG.

Fam Pract. 2009 Aug;26(4):260-8. doi: 10.1093/fampra/cmp026. Epub 2009 May 7.


Supplemental Content

Loading ...
Support Center